ReviewWiener medizinische Wochenschrift (1946)2010
An overview on bone manifestations in Gaucher disease.
Review in Wiener medizinische Wochenschrift (1946), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Gaucher: A Systematic Review on Oral and Radiological Aspects.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Gaucher disease: the hematologist's perspective of a multisystemic disorder.Annals of hematology · 2026Review
- Transcriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease.Life (Basel, Switzerland) · 2026Article
- Gaucher disease, state of the art and perspectives.Journal of internal medicine · 2025Review
- Genotype Meets Phenotype: Unraveling Gaucher's Genetic Landscape in the Indian Population.Cureus · 2025Review
- The Diagnosis and Therapy of Osteoporosis in Gaucher Disease.Calcified tissue international · 2025Review
- Abnormally accumulated GM2 ganglioside contributes to skeletal deformity in Tay-Sachs mice.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Machine Learning-Driven Biomarker Discovery for Skeletal Complications in Type 1 Gaucher Disease Patients.International journal of molecular sciences · 2024Article
- Article
- [Importance of lysosomal storage diseases in rheumatology].Zeitschrift fur Rheumatologie · 2024Review
- Women with Gaucher Disease.Biomedicines · 2024Review
- A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach.International journal of biological sciences · 2024Review
- Gaucher-like Cells in Thalassemia Intermedia: Is It a Challenge?Diseases (Basel, Switzerland) · 2023Article
- Article
- Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa.Journal of osteoporosis · 2023Article
- Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease.Frontiers in medicine · 2023Article
- Clinical and radiological evaluation of dentomaxillofacial involvement in Type I Gaucher disease.Oral radiology · 2022Article
- Rare Case of Gaucher's Disease Presenting as a Solitary Swelling of the Proximal Tibia Mimicking a Musculoskeletal Tumor in an Adult: A Case Report.Journal of orthopaedic case reports · 2022Article
- Parkinson's in the bone.Cell & bioscience · 2021Review
- Survey about the Quality of Life of Italian Patients with Fabry Disease.Diseases (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gaucher disease (GD), the most prevalent lysosomal storage disorder, affects multiple organ systems. Patients with non-neuronopathic (type 1) GD, the most common form of GD, present with hepatomegaly, splenomegaly, anemia, bleeding tendencies, thrombocytopenia, skeletal pathologies, growth retardation, and, in severe cases, pulmonary disease. The bone manifestations include bone infarcts, avascular bone necrosis, lytic lesions, osteosclerosis, fractures due to osteopenia or osteoporosis, and rarely acute osteomyelitis. Bone pain of varying intensity, fractures, and progressive joint collapses may cause impaired mobility and performances status, and increased morbidity. Enzyme replacement therapy and substrate reduction therapy have demonstrated to have beneficial effects on bone pain, bone crises, and the extent of osteoporosis. This review article gives an overview of the clinical appearance of bone pathology in GD, the possible pathophysiological mechanisms, diagnostic approaches, and the therapeutic effects of enzyme replacement therapy, substrate reduction therapy, and bone specific therapies as evaluated in current literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.